AYTU BIOPHARMA, INC (AYTU) - Dilution Analysis

10-Q filing | 10.5M shares outstanding

10-Q filing | 9.4M shares outstanding

10-K filing | 9.0M shares outstanding

8-K filing: Aytu BioPharma, Inc. entered into an underwriting agreement for a public offering of 1,366,668 shares of common stock at $1.50 per share and 8,233,332 prefunded warrants at $1.4999 per warrant, with net proceeds expected to be approximately $12.9 million.

S-1/A filing: The proposed maximum aggregate offering price of common stock will be reduced based on the offering price of any prefunded warrants issued in the offering, and the proposed maximum aggregate offering price of the prefunded warrants will be reduced based on the offering price of any shares of Common Stock issued in the offering.

S-1 filing: This S-1 filing outlines the terms of a proposed offering of common stock and pre-funded warrants, including representations, warranties, and agreements between the company and the underwriters.

10-Q filing | 6.1M shares outstanding

10-Q filing | 6.1M shares outstanding

10-Q filing | 6.1M shares outstanding

10-K filing | 5.5M shares outstanding

S-3 filing: The company files an S-3 form to register the offering of debt securities, common stock, preferred stock, warrants, rights, and units up to $100,000,000.

10-Q filing | 5.5M shares outstanding

10-Q filing | 5.5M shares outstanding

10-Q filing | 5.5M shares outstanding

10-K filing | 5.5M shares outstanding

8-K filing: Aytu BioPharma, Inc. entered into a securities purchase agreement to issue and sell 1,743,695 shares of common stock, pre-funded warrants to purchase 430,217 shares of common stock, Tranche A warrants to purchase 2,173,912 shares of common stock, and Tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering, expected to close on June 13, 2023, with gross proceeds of approximately $4 million. ($4.0M proceeds)

S-1/A filing: The filing is an S-1/A registration statement for a best-efforts offering of up to 4,938,271 shares of common stock, Tranche A Warrants, Tranche B Warrants and Pre-Funded Warrants.

10-Q filing | 3.7M shares outstanding

S-1 filing: AYTU BioPharma is offering up to 4,938,271 shares of common stock at an assumed price of $2.43 per share, along with pre-funded warrants to purchase one share of common stock, and has engaged Maxim Group LLC as the exclusive placement agent.

10-Q filing | 3.6M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 62,429,445 → 3,400,000

10-Q filing | 62.4M shares outstanding

10-K filing | 38.6M shares outstanding

8-K filing: Aytu BioPharma, Inc. entered into an underwriting agreement to issue and sell 21,505,814 shares of common stock, pre-funded warrants to purchase 1,750,000 shares of common stock, and warrants to purchase 23,255,814 shares of common stock at a combined price of $0.43 per share/warrant or $0.429 per pre-funded warrant/warrant, with estimated net proceeds of $9.1 million.

S-3 filing: This prospectus relates to the resale of 867,769 shares of Common Stock, par value $0.0001 per share of Aytu BioPharma, Inc. by Avenue Venture Opportunities Fund, LP and Avenue Venture Opportunities Fund II, LP. The Common Stock is issuable upon the exercise of 867,769 warrants of the Company issued to the Selling Stockholders pursuant to the loan and security agreement dated January 26, 2022.

10-Q filing | 33.4M shares outstanding

10-Q filing | 30.0M shares outstanding

10-Q filing | 25.6M shares outstanding

10-K filing | 27.5M shares outstanding

S-3 filing: The company files an S-3 shelf registration to offer debt securities, common stock, preferred stock, warrants, rights, and units, up to a total amount of $100,000,000.

10-Q filing | 25.2M shares outstanding

8-K filing: Aytu BioPharma, Inc. issued 102,759 shares of common stock valued at $1.0 million to holders of Contingent Value Rights relating to the merger with Innovus Pharmaceuticals, Inc. due to achieving a milestone. ($1.0M proceeds)

10-Q filing | 17.9M shares outstanding

8-K filing: Aytu BioScience, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC to sell 4,166,667 shares of common stock at $6.00 per share, with an option for Wainwright to purchase an additional 625,000 shares. ($25.0M proceeds)

10-Q filing | 125.8M shares outstanding

10-K filing | 17.5M shares outstanding

8-K filing: Aytu BioScience, Inc. entered into Restricted Stock Cancelation and Exchange Agreements (RSCE Agreement) with officers and directors to exchange their right, title and interest in their respective share of the November Equity Grant for cash. Additionally, the company granted options and restricted stock to the CEO and CFO and issued warrants to H.C. Wainwright & Co., LLC. ($0.84M proceeds)

8-K filing: Aytu BioScience, Inc. entered into an Asset Purchase Agreement with Cerecor Inc. to purchase certain assets, and assume certain liabilities, from Cerecor for approximately $32 million in cash, shares of Aytu Series G Preferred Stock, and assumption of obligations. Additionally, they entered into Securities Purchase Agreements for the issuance and sale of Series F Convertible Preferred Stock and warrants.

S-3 filing: This S-3 filing relates to an at-the-market offering of common stock, with an aggregate offering price of up to $40.0 million, to be offered through Jefferies LLC, primarily intended for working capital and general corporate purposes.

10-Q filing | 17.5M shares outstanding

8-K filing: Aytu BioScience, Inc. entered into a securities purchase agreement to sell and issue 12,539,197 shares of common stock and warrants to purchase up to 12,539,197 shares at a price of $1.595 per share, for gross proceeds of $20.0 million. ($20.0M proceeds)

8-K filing: Aytu BioScience, Inc. completed a registered direct offering on March 13, 2020, selling 16,000,000 shares of common stock at $1.25 per share and warrants to purchase up to 16,000,000 shares, resulting in gross proceeds of $20.0 million before deducting fees. ($20.0M proceeds)

8-K filing: Aytu BioScience, Inc. entered into a securities purchase agreement to sell 4,450,000 shares of common stock at $1.15 per share and pre-funded warrants to purchase up to 3,376,087 shares of common stock at an effective price of $1.15 per share, for aggregate gross proceeds of approximately $9.0 million. ($9.0M proceeds)

S-3 filing: This prospectus relates to the resale of 9,805,845 shares of Common Stock issuable upon the conversion of 9,805,845 shares of Series G Convertible Preferred Stock by Cerecor Inc.

10-Q filing | 17.5M shares outstanding